tert-butyl (R)-(1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl)(methyl)carbamate | 929716-71-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl (R)-(1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl)(methyl)carbamate
• 英文别名: tert-butyl [(3R)-1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl]methyl-carbamate；tert-butyl N-[(3R)-1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl]-N-methylcarbamate
• CAS: 929716-71-2
• 化学式: C₁₄H₂₂ClN₅O₂
• 分子量: 327.814
• InChiKey: QWYWJIGXQIQZAB-SECBINFHSA-N

物化性质

• 沸点：
  513.6±60.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  84.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (R)-(1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl)(methyl)carbamate 在 盐酸 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 22.0h， 生成 (R)-4-(1-methyl-1H-pyrazol-5-yl)-6-(3-(methylamino)pyrrolidin-1-yl)pyrimidin-2-amine dihydrochloride
  参考文献：
  名称：

  WO2020079457A5

  摘要：

  公开号：

  WO2020079457A5
• 作为产物：
  描述：

  2-氨基-4,6-二氯嘧啶 、 (R)-3-(N-BOC-N-甲氨基)吡咯烷 在 2-氨基-4,6-二氯嘧啶 作用下， 以87的产率得到tert-butyl (R)-(1-(2-amino-6-chloropyrimidin-4-yl)pyrrolidin-3-yl)(methyl)carbamate
  参考文献：
  名称：

  Pyrimidine derivatives

  摘要：

  化合物的式子（I）或其药学和/或兽医学可接受的衍生物，其中R1、R2、R3、R4、R5和R8如上所定义。

  公开号：

  US20070185075A1

文献信息

• WO2007/31529
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery and SAR of 6-Alkyl-2,4-diaminopyrimidines as Histamine H₄ Receptor Antagonists
  作者：Brad M. Savall、Frank Chavez、Kevin Tays、Paul J. Dunford、Jeffery M. Cowden、Michael D. Hack、Ronald L. Wolin、Robin L. Thurmond、James P. Edwards

  DOI：10.1021/jm401727m

  日期：2014.3.27

  This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.
• PYRIMIDINE DERIVATIVES
  申请人：Ziarco Pharma Ltd

  公开号：EP1966162B1

  公开（公告）日：2017-03-15
• PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS
  申请人：Heptares Therapeutics Limited

  公开号：US20210300906A1

  公开（公告）日：2021-09-30

  The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A; X; n; R 1 and R 2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
• US7943628B2
  申请人：——

  公开号：US7943628B2

  公开（公告）日：2011-05-17